Elli Kaplan, CEO, is the co-founder and CEO of Neurotrack. Her career spans two decades in the public and private sectors, at the White House, the State and Treasury Departments, and the United Nations Development Program. She has also held senior positions with AIG Capital Partners, Goldman Sachs and multiple startups. She is a graduate of Mount Holyoke College and has an M.B.A. from Harvard Business School.
Elli Kaplan, CEO
Headquarters: Palo Alto, CA
Neurotrack is transforming the diagnosis of Alzheimer’s disease. Through a safe and non-invasive test, its technology can predict the risk of developing mild cognitive impairment and Alzheimer’s disease years before symptoms occur. Conceived at Emory University and validated by a 5-year study funded by the National Institutes of Health (NIH), it will give pharmaceutical companies better tools to recruit patients for clinical trials, leading to the development of life-saving drugs.
Neurotrack is backed by Founders Fund and Social + Capital, and was the winner of more than $7M in grants from the NIH. It was named Best Health Company at SXSW, DEMO, and participated in the Rock Health accelerator.